Bli medlem
Bli medlem

Du är här



Hofseth International AS, a partly owned company by Chairman Roger Hofseth and primary insider in Hofseth BioCare ASA has today, Monday 18 January 2016, entered into an agreement to purchase 322,777 shares in HBC owned directly or indirectly by Øystein Omvik, in connection with Øystein Omvik's search for new challenges and resigning his position as Chief Financial Officer as of 18 January 2016.
The shares is purchased at a price of NOK 3.25, corresponding to a total compensation of NOK 1,049,025.25. After this transaction, Hofseth International AS owns a total of 2,474,063 shares in HBC, which represents 2.24 % of the total outstanding shares. Øystein Omvik will after the transaction hold no shares directly or indirectly in HBC.
For more information, please contact:

Jon Olav Ødegård, CEO Hofseth BioCare ASA
Mobile: +47 936 32 966
About Hofseth BioCare:

Hofseth BioCare is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, Hofseth BioCare is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. Hofseth BioCare`s objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Hofseth Biocare ASA via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.